Genmab — April 2016
-
-
Det er ikke ligefrem fordi nyheden har ramt medierne som en steppebrand...
-
Ja der står ikke andet i det statement end at de vil komme med et statement sammen med Janssen http://ir.genmab.com/releasedetail.cfm?ReleaseID=963424
-
Det her er hverdag i den branche.
-
Fra Novod: The suit has not been commented by JNJ but we would expect JNJ to of course deny any wrongdoing or patent infringement. Also, we expect that JNJ has made an extremely thorough due dilligence on CD38 IP before entering the deal with Genmab back in 2012. Furthermore we believe that JNJ will vigorously defend its IP rights and successfully win potentially legal battles against Morphysys. There will be lots of focus on this, but we view any kind of Genmab weakness as a great buying opp.
-
Sanofi har også lige fået et sagsanlæg på Lixilan. Den slags tager mange år og gør advokater meget rige.
-
Biotekselskab lægger sag an mod Genmab
Et tysk biotekselskab mener, at Genmab og partneren Janssen med kræfthåbet Darzalex krænker et patent og har derfor anlagt en retssag ved en amerikansk domstol.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind